2026-01-27 - Analysis Report
**Company Overview**
AbbVie is a biopharmaceutical company that develops and markets a range of pharmaceutical and nutritional products.

**Return Rate Comparison**

* Return rate of AbbVie stock (ABBV): 182.18%
* Return rate of S&P 500 stock (VOO): 127.58%
* Difference in cumulative return on the last day of the data: 54.60%

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|--------|
| 2016-2018  | 35.0% | 23.1% | 26.0% | 1.0 | 162.9B |
| 2017-2019  | 27.0% | 23.1% | 2.0% | 1.1 | 156.5B |
| 2018-2020  | -19.0% | 32.9% | -43.0% | 0.8 | 189.4B |
| 2019-2021  | 77.0% | 32.9% | 13.0% | 0.7 | 239.3B |
| 2020-2022  | 100.0% | 32.9% | 96.0% | 0.6 | 285.6B |
| 2021-2023  | 54.0% | 19.5% | 36.0% | 0.4 | 273.9B |
| 2022-2024  | 33.0% | 19.5% | 4.0% | 0.3 | 314.1B |
| 2023-2025  | 84.0% | 20.4% | 9.0% | 0.3 | 403.8B |

**Recent Stock Price Fluctuations**

* Close: $220.77
* 5-day Simple Moving Average (SMA): $217.67
* 20-day SMA: $222.61
* 60-day SMA: $224.94

**RSI, PPO Index Indicators**

* Market Risk Indicator (MRI): 0.70 (Medium Investment)
* RSI: 50.69
* PPO: -0.09
* Hybrid Signal: Buy (Cash 0%)
* Delta_Previous_Relative_Divergence: improving
* 7-day Rank change: rank down
* 7-day Dynamic Expected Return change: worsening
* Expected Return (%): 24.40%

**Recent News & Significant Events**

* [2026-01-26] AbbVie Rose 2% Last Week. Hereâ€™s Why Investors Looked Past Trial Risk - TIKR.com (news.google.com)
* [2026-01-26] How Recent Price Target Rethinks Are Rewriting The Story For AbbVie (ABBV) - Yahoo Finance UK (news.google.com)
* [2026-01-26] AbbVie Inc. $ABBV Stake Cut by Lbp Am Sa - MarketBeat (news.google.com)
* [2026-01-12] 3 No-Brainer Dividend Stocks to Buy Right Now - The Motley Fool (news.google.com)
* [2026-01-24] AbbVie is a top dividend stock as drug pipelines drive payout hikes - thestreet.com (news.google.com)
* [2026-01-22] March 6th Options Now Available For AbbVie (ABBV) - Nasdaq (news.google.com)

**Analyst Opinions**

* Key: Buy
* Mean (1=StrongBuy~5=Sell): 1.93 (~Buy)
* Opinions: 27
* Target Price (avg/high/low): 245.22 / 289.00 / 184.00

**Comprehensive Analysis**

Based on the analysis of AbbVie's return rate, alpha, beta, and recent stock price fluctuations, it appears that the stock has been performing well, with a cumulative return of 182.18% compared to 127.58% for the S&P 500. The stock's alpha and beta analysis also indicate a strong performance, with a mean opinion of Buy and a target price of $245.22.

However, the recent news and significant events suggest that investors may be looking past trial risks and focusing on the company's strong dividend portfolio. The Market Risk Indicator (MRI) indicates a medium investment risk, which is consistent with the RSI and PPO index indicators.

Overall, the comprehensive analysis suggests that AbbVie is a strong performer in the biopharmaceutical industry, with a solid dividend portfolio and a strong expected return of 24.40%. However, investors should be aware of the trial risks associated with the company's products and the potential impact on the stock's performance.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.